Skip to search formSkip to main contentSkip to account menu

elliptinium acetate

Known as: ellipticinium acetate, 2-methyl-9-hydroxyellipticinium acetate, 9-Hydroxy-2-methylellipticinium acetate 
Acetate salt of elliptinium, a derivative of the alkaloid ellipticine isolated from species of the plant family Apocynaceae, including Bleekeria… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

Celiptium

Broader (1)

elliptinium

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
In vitro cytotoxicity of S16020-2, a new olivacine derivative
SummaryS16020-2 is a new olivacine derivative which has recently shown a marked antitumor activity in various experimental models… 
Highly Cited
1992
Highly Cited
1992
Probing intercalation and conformational effects of the anticancer drug 2-methyl-9-hydroxyellipticinium acetate in DNA fragments with circular dichroism.
Circular dichroism was applied to the analysis of drug-DNA associations. With the octanucleotide d(TGACGTCA) (octanucleotide I… 
1986
1986
Covalent binding of elliptinium acetate (NSC 264137) to nucleic acids of L1210 cells in culture.
Elliptinium acetate (9-OH-NME; Celiptium) is an antineoplastic agent currently used in the treatment of metastatic breast cancer… 
1986
1986
Ribose as the preferential target for the oxidized form of elliptinium acetate in ribonucleos(t)ides. Biological activities of the resulting adducts.
The covalent binding of the oxidized form of elliptinium acetate, an antitumor drug, to various ribonucleos(t)ides is described… 
1984
1984
Ellipticine derivatives interacting with model membranes. Influence of quaternarization of nitrogen-2.
1984
1984
Regioselective arylation of ribose in adenosine and guanosine with the antitumor drug N2-methyl-9-hydroxyellipticinium acetate.
The transformation of the antitumor drug N2-methyl-9-hydroxy-ellipticinium by a peroxidase-hydrogen peroxide system, which has… 
1984
1984
Covalent binding of the antitumor agent N2-methyl-9-hydroxy-ellipticinium acetate (NSC 264137) on RNA and poly A in vitro.
1982
1982
Pharmacokinetics of 2-methyl-9-hydroxyellipticinium acetate (NSC-264137) in cancer patients (phase I study).
1982
1982
Phase I clinical study of 9-hydroxy-2N-methyl-ellipticinium acetate (NSC-264137) administered on a 5-day i.v. schedule.
1978
1978
Some antitumor derivatives of ellipticine deprived of mutagenic properties.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)